Abstract
As proteins and peptides (hereinafter referred to collectively as “proteins”) are major components of biological processes, it is logical to assume that their potential for use as therapeutics would be extremely high. However, the recognizable need for a defense system has implications for the administration of protein-based pharmaceuticals (Table 1). Minor differences in the primary structure of proteins—even as little as one amino acid from the human form of the protein—have been shown to be sufficient for immune system recognition.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Aalberse RC, van der Gaag R, van Leeuwen J (1983) J Immunol 130: 722 – 726
Aalberse RC, Heber D, Liebermann J (1983) Clin Exp Immunol 52: 164 – 172
Abramowicz D, Crusiaux A, Goldman M (1992) N Engl J Med 327: 736
Abramowicz D, Schandend L, Goldman M, Crusiaux A, Veerstraeten P, De Pauw L, Wybran J, Kinnaert P (1989) Transplantation 47: 606 – 608
Adair JR (1992) Immunol Rev 130: 5 – 40
Ahmad I, Longenecker M, Samuel J, Allen TM (1993) Cancer Res 53: 1484 – 1488
Alegre ML, Collins AM, Pulito VL, Borsius RA, Olson WC, Zivin RA, Knowles R, Thistlewaithe JR, Jolliffe LK, Bluestone JA (1992) J Immunol 148: 3461 – 3468
Alegre ML, Peterson LJ, Xu D, Sattar HA, Jeyarajah DR, Kowalkowski K, Thistlewaithe JR, Zivin RA, Jolliffe L, Bluestone JA (1994) Transplantation 57: 1537 – 1543
Alexopoulos A, Raine AEG, Cobbe SM (1984) Eur Heart J 5: 1010 – 1012
Alkan SS, Towbin H, Hochkeppel HK (1988) J Interferon Res 8: 25 – 33
Allegretta MA, Atkins B, Dempsey RA, Bradley EC, Konrad MW, Childs A, Wolfe SN, Mier JW (1986) J Clin Immunol 6: 481 - 490
Allen TM (1994) Adv Drug Del Rev 13: 285 – 309
Allen TM (1994) Trends Pharmacol Sci 15: 215 – 220
Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Biochim Biophys Acta 1066: 77 – 82
Allison AC, Gregoriadis G (1974) Nature 252: 252
Altman JJ (1983) Lancet ii:524
Alving CR, Steck EA, Chapman WL Jr, Waits VB, Hendricks LD, Swartz GM Jr, Hanson WL (1978) Proc Natl Acad Sci USA 75: 2959 – 2963
Alving CR, Steck EA, Hanson WL, Loizeaux PS, Chapman WL Jr, Waits VB (1980) Ann Life Sci 26: 2231 – 2238
Andreani D (1973) Excerpta Med Int Congr Ser 316: 68 – 75
Andrew SM, Pimm MV, Perkins AC, Baldwin RW (1986) Eur J Med 12:168–175 Arnold FH (1993) FASEB J 744–749
Arturrson P, Edman P, Sjoholm I (1984) J Pharmacol Exp Ther 231: 705 – 712
Arturrson P, Edman P, Sjoholm I (1985) J Pharmacol Exp Ther 234: 255 – 260
Asselin BL, Whiten JC, Coppola DJ, Rupp IP, Sallan JE, Cohen HJ (1993) J Clin Oncol 9: 1780 – 1786
Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ (1993) J Clin Oncol 11: 1780
Aston R, Holder AT, Ivanyi J, Bomford R (1987) Mol Immunol 24: 143 – 150
Baca M, Alewood PF, Kent SB (1993) Protein Sci 2: 1085 – 1091
Bachmair A, Finley D, Varshavsky A (1986) Science 234: 179 – 186
Bakker-Woudenberg IAJM, Lokerse AF, ten Kate MT, Mouton JW, Woodie MC, Storm G (1993) J Infect Dis 168: 164 – 171
Ball P (1994) Nature 367: 323 – 324
Barry BW, Southwell D, Woodford RJ (1984) Invest Dermatol 82: 49 – 52
Barton NW, Brady RO, Doppelt SM, Hill SC, Bisceglia AM, Hill SC, Verderese CL, Graham OC, Argoff CE, Grewel RP, Yu K-T (1990) Clin Res 38:457a
Batra JK, Chaudhary VK, FitzGerald D, Pastan I (1990) Biochem Biophys Res Commun 171: 1 – 6
Belmont J, Caskey CT (1986) Developments leading to gene therapy. In: Kucherlapati R (ed) Gene therapy. Plenum, New York, pp 411 – 440
Benziger DP, Edelson J (1983) Drug Metab Rev 14: 137 – 168
Berson SA, Yalow RS (1959) J Clin Invest 38: 2017 – 2025
Berson SA, Yalow RS (1964) Diabetes 13: 247 – 259
Berson SA, Yalow RS (1966) Am J Med 40: 676 – 690
Berson SA, Yalow RS, Bauman A, Rothschild MA, Newerly K (1956) J Clin Invest 35: 170 – 190
Bickel U, Yoshikawa T, Landaw EM, Faull KF, Pardridge WM (1993) Proc Natl Acad Sci USA 90: 2618 – 2622
Bierich JR (1986) Acta Paediatr Scand 325:13-18 Blakely DC (1992) Acta Oncol 31: 91 – 97
Blandford et al (1984) JAMA 251 (11): 1459 – 1460
Bliss M (1982) The discovery of insulin. McClelland and Stewart, Toronto
Blume G, Cevc G (1990) Biochim Biophys Acta 1029: 91 – 97
Blume G, Cevc G (1993) Biochim Biophys Acta 1146: 157 – 268
Bode C, Runge MS, Branscomb EE, Newell JB, Matsueda GR, Haber E (1989) J Biol Chem 264: 944 – 948
Boerman OC, Mijnheere EP, Broers JLV, Voojis GP, Ramaekers FCS (1991) Int J Cancer 48: 457 – 462
Bos R, Siegel K, Otter M, Nieuwenhuizen W (1992) Fibrinolysis 6: 173 – 182
Brackman HH, Egli H (1981) Treatment of hemophilia patients with inhibitors. In: Seligohy U, Rimon A, Horoszowski H (eds) Hemophilia. Castle House, London, p 113
Brackman HH, Gormsen J (1977) Lancet ii:933
Branscomb EE, Runge MS, Savard CE, Adams KM, Matsueda GR, Haber E (1990) Thromb Haemost 64: 260 – 266
Brasseur F, Couvreur P, Kante B, Deckers-Passau L, Roland M, Deckers C, Speiser P (1980) Eur J Cancer 16: 1441 – 1445
Britton DE, Leinikki PO, Barranger JA, Brady RO (1978) Life Sci 3 (25): 2517 – 2520
Brodgen RN, Heel RC (1987) Drugs 34: 350 – 371
Broome JD (1961) Nature 191: 1114 – 1115
Brunfeldt K, Deckert T (1966) Acta Endocrinol (Copenh) 47: 367 – 370
Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ (1989) Cancer Res 49: 6153 – 6160
Carpenter FH (1958) Arch Biochem Biophys 78: 539 – 545
Carveth-Johnson AO, Mylvaganam K, Child DF (1982) Lancet ii:1287
Chance RE, Root MA, Galloway JA (1976) Acta Endocrinol (Copenh) 83 [Suppl 205]: 185 – 196
Chang TMS (1964) Science 146: 524 – 545
Chang TMS (1972) Artificial cells. Thomas, Springfield
Chapman WL, Hanson WL, Alving CR, Hendricks LD (1984) Am J Vet Res 45: 1028 – 1030
Charpie JR, Runge MS, Matsueda GR, Haber E (1990) Biochemistry 29: 6374 – 6378
Chatenoud L, Baudrihaye MF, Chkoff N, Kries H, Goldstein G, Bach JF (1986) J Immunol 137: 830 – 838
Chatenoud L, Jonker M, Villemain F, Goldstein G, Bach J (1986) Science 232: 1406 – 1408
Chaudhary VK, Gallo MG, FitzGerald DJ, Pastan I (1990) Proc Soc Natl Acad Sci USA 87: 9491 – 9494
Chien YW (1983) Drug Dev Ind Pharm 9: 1291 – 1330
Cho M, Gilbert CW, Campbell K, Pschenyczny V, Martin R, Ginns E, Shorr RGL (1994) FASEB J 8: A94
Christy M, Deckert T, Nerup J (1977) Clin Endocrinol Metab 6: 305 – 322
Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER (1993) Ann Allergy 70: 462 – 466
Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER (1993) Ann Allergy 70: 462
Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbeil NJ, Blattner SR, Tantracahi K, Leavitt P, Sallan SE (1986) N Engl J Med 315: 657 – 663
Cohen AM, Martin EW, Lavery I, Daly J, Sardi A, Aitken D, Bland K, Mojzisik C, Hinkle G (1991) Arch Surg 126: 349 – 352
Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, Dodd SW, Pantoliano MW, Milenic DE, Schlom J (1990) J Natl Cancer Inst 82:1191-1197 Collins FS (1991) Hosp Pract 26: 93 – 98
Couvreur, Kante P, Grislain L, Roland M, Speiser PJ (1982) Pharm Sei 71: 790 – 792
Couvreur P, Kante B, Lenaerts V, Scaidteur V, Roland M, Speiser PJ (1980) Pharm Sei 69: 199 - 202
Couvreur P, Kante B, Roland M, Guiot P, Bauduin P, Speiser PJ (1979) Pharm Pharmacol 31: 331 – 332
Davis S, Abuchowski A, Park YK, Davis FF (1981) Clin Exp Immunol 46:649 Davis SS (1992) J Pharm Pharmacol 44: 186 – 190
de Vries ME, Bodde HE, Verhoef JC, Junginger HE (1991) Crit Rev Ther Drug Carrier Sys 8: 271 – 303
Deckert T, Andersen OO, Grundahl E, Kerp L (1972) Diabetologia. 8: 358 – 361
Delgado C, Francis GE, Fisher D (1992) Crit Rev Ther Drug Carr Syst 9: 249 – 304
di Mario UD, Arduini P, Tiberti C, Lombardi G, Pietravalle P, Andreani D (1986) Diabetes Res Clin Pract 2: 317 – 324
Dreborg S, Akerblom EB (1990) Crit Rev Ther Drug Carrier Syst 6: 315 – 365
Drewes PA, Kamp AO, Winkelman JW (1978) Experientia. 34: 316 – 318
Duncan R, Spreafico F (1994) Clin Pharmacokinet 27: 290 – 306
Duncan R (1985) Crit Rev Ther Drug Carrier Syst 1: 281 – 310
Dykiewicz MS, Kim HW, Orfan N, Yoo TJ, Leiberman P (1994) J Allergy Clin Immunol 93: 117 – 125
Edman P, Sjoholm I (1982) Life Sci 30: 327 – 330
Elias PM, Friend DS (1975) J Cell Biol 65: 180 – 191
Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davey FR, Glicksman AS, Bloomfield CD, Holland JF (1991) J Clin Oncol 9: 2002 – 2015
Enna SJ, Schanker LS (1972) Am J Physiol 223: 1227 – 1231
Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H (1979) Cancer Res 39: 3893 – 3896
Evans WE, Tsiatis A, Rivera G, Murphy SB, Dahl GV, Denison M, Crom WR, Barker LF, Mauer AM (1982) Cancer 49: 1378 – 1383
Ewing NP, Sanders NL, Dietrich SL, Kasper CK (1988) JAMA 259: 65 – 68
Fagnani R, Hagan MS, Bartholomew R (1990) Cancer Res 50: 3638 – 3645
Feinglos MN, Jegasothy BV (1979) Lancet i:122–124
Fersht A, Winter G (1992) Trends Biochem Sci 17: 292 – 295
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ (1982) Diabetes Care 5: 107 – 113
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S (1983) Diabetologia 25: 465 – 469
Fireman P, Fineberg SE, Galloway JA (1982) Diabetes Care. 5: 119 – 125
Fisher AN, Brown K, Davis SS, Parr GD, Smith DA (1987) J Pharm Pharmacol 39: 357 – 362
Fisher AN, Farraj NF, O’Hagan DT, Jabbal-Gill I, Johansen BR, Davis SS, Ilium L (1991) Int J Pharm 74: 147 – 156
Fisher NF (1923) Am J Physiol 67: 65 – 71
Franklin RR, Dukes CD (1964) J Am Med Assoc 190: 682 – 683
Freeman SM, Whartenby KA, Abraham GN, Zweibel JA (1993) Adv Drug Del Rev 12: 169 – 183
Frienkel RK (1983) In: Goldsmith LA (ed) Biochemistry and physiology of the skin, vol I. Oxford University Press, Oxford, p 328
Fujita H, Okamoto M, Takao A (1991) Drug Delivery Syst 6: 133 – 138
Fujita T, Furitsu H, Nishikawa M, Takakura H, Sezaki H, Hashida M (1992) Biochem Biophys Res Commun 189: 191 – 196
Fujita T, Nishikawa M, Tamake C, Takakura Y, Hashida M, Sezaki H (1992) J Pharmacol Exp Ther 263: 971 – 978
Fujita T, Nishikawa M, Tamaki C, Takakura T, Hashida M, Sezaki H (1992) J Pharmacol Exp Ther 263: 971 – 978
Fujita T, Yasuda Y, Takakura Y, Hashida M, Sezaki H (1990) 11: 149 – 154
Fung W-P, Przybylski M, Ringsdorf H, Zaharko D (1979) J Natl Cancer Inst 62: 1261 – 1264
Gabizon A, Papahadjopoulos D (1988) Proc Natl Acad Sci USA 85: 6949 – 6953
Gabizon A, Shiota R, Papahadjoupoulos D (1989) J Natl Cancer Inst 81:1484-1488 Gabizon AA (1992) Cancer Res 52: 891 – 896
Galloway JA, Fineberg SE, Fineberg NS, Goldman J (1982) Effect of purity and beef content on complications of insulin therapy. In: Gueriguian JL, Bransone ED, Outschoorn AS (eds) Hormone drugs. Proceedings of the FD A-USP workshop on drug and reference standards for insülins, somatotropins and thyroid-axis hor¬mones, Bethesda, MD. USP Convention, pp 244 – 253
Garcia-Ortega P (1984) Br Med J 288: 1271
Gasparini M, Ripamonti M, Seregni E, Regalia E, Buraggi GL (1988) Int J Cancer [Suppl] 2: 81 – 84
Ghose T, Norvell ST, Guclu A, Bodurtha A, Mac Donald AS (1977) J Natl Cancer Inst 58: 845 – 852
Godal A, Fodstad O, Pihl A (1989) Int J Cancer 32: 515 – 521
Goldstein G (1987) Transplant Proc 19 [2 Suppl 1]: 1 – 6
Goldstein G, Fuccello AJ, Norman DJ, Shield CF, Colvin RB, Cosimi AB (1986) Transplantation 42: 507 – 511
Goodenough PW, Jenkins JA (1991) Biochem Soc Trans 19: 655 – 662
Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummer D (1990) J Clin Oncol 8: 1093 – 1092
Gossain W, Rovner OR, Mohan K (1985) Ann Allergy 55: 116 – 118
Gould BJ, Borowitz MJ, Groves ES, Carter PW, Anthony D, Weiner LM, Frankel AE (1989) J Natl Cancer Inst 81: 775 – 781
Grabowski GA, Barton NW, Pastores G, DAmbrosia JM, Banerjee TK, McKee MA, Parker C, Schiffmann R, Hill SC, Brady RO (1995) Ann Intern Med 122: 33 – 39
Grabowski GA, Pastores G, Brady RO, Barton NW (1993) Pediatr Res 33 (4 pt 2):819a Grammar LC, Metzger BE, Patterson R1 (1984) JAMA 251: 1459 – 1460
Grammer L (1986) Clin Rev Allergy 4: 189 – 200
Graybill JR, Cravin PC, Taylor RL, Williams DM, Magee WE (1982) J Infect Dis 145: 748 – 752
Gregoriadis G (ed) (1984) Liposome technology, vol 1–3. CRC Press, Boca Raton
Gregoriadis G, Neerunjun ED (1975) Biochem Biophys Res Commun 65: 537 – 544
Gribben JG, Devereux S, Thomas NSB, Keim M, Jones HM, Goldstone HA, Lynch DC (1990) Lancet 335: 434 – 437
Guy RH, Hadgraft J (1985) Int J Pharm Int 24: 267 – 274
Habeeb AFSA, Cassidy HG, Singer SF (1958) Biochim Biophys Acta 29: 587 – 593
Haller DG (1988) J Clin Oncol 6: 1213 – 1215
Heath TD (1987) Methods Enzymol 149: 111 – 118
Hellstrom KE, Hellstrom I, Brown JP (1984) Med Oncol Tumor Pharmacother 1: 143 – 147
Higaki JN, Fletterick RJ, Craik CS (1992) Trends Biochem Sei 173: 100 – 104
Hirano T, Ohashi S, Morimoto S, Tsuda K, Kobayashi T, Tsukagoshi S (1986) Makromol Chem 187: 2815 – 2824
Hirayama S, Sato F, Oda T, Maeda H (1986) Jpn J Antibiot 39: 815 – 822
Hirsch R, Chatenoud L, Gress RE, Sachs DH, Bach JF, Bluestone JA (1989) Transplantation 47: 853 – 857
Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH (1986) Drug Metab Disp 14: 349
Ho DH, Wang CY, Lin JR, Brown N, Newman RA, Krakoff IH (1988) Drug Metab Disp 16: 27
Holder AT, Aston R, Preece MA, Ivanyi J (1985) J Endocrinol 107: R9 – R12
Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D (1992) Cancer Res 52: 5135 – 5143
Hughes M, Vassilakos A, Andrews DW, Hortelano G, Belmont JW, Chang PL (1994) Human Gene Ther 5: 1445 – 1455
Itri LM, Campion M, Dennin RA, Palleroni AV, Gutterman JU, Groopman JE, Trown PW (1987) Cancer 59: 668 – 674
Jaffers GJ, Fuller TC, Cosimi AB, Russell PS, Winn HJ, Colvin RB (1986) Transplantation 41: 572 – 578
Jain RK (1990) Cancer Metast Rev 9: 253 – 266
Johnsson K, Alleman RK, Widmer H, Benner SA (1993) Nature 365: 530 – 532
Jones B, Holland JF, Glide well O, Jacquillat C, Weil M, Pochedly C, Sinks L, Chevalier L, Mauier HM, Koch K, Falkson G, Patterson R, Seligman B, Sartorius J, Kura F, Haurani F, Stuart M, Bergeri EO, Ruymann F, Sawitsky A, Forman E, Pluess H, Truman J, Hakami N (1979) Med Pediatr Oncol 3: 387 – 400
Jones VE, Leskowitz S (1965) Nature 207: 596 – 597
Juliano RL, Stamp D (1976) Nature 261: 235 – 237
Kaarsholm NC, Norris K, Jorgenson RJ, Mikkelsen J, Ludvigsen S, Olsen OH, Sorenson AR, Havelund S (1993) Biochemistry 32: 10773 – 10778
Kaplan SL, August GP, Biethen SL, Brown DR, Hintz RL, Johansen A, Plotnick LP, Underwood LE, Bell JJ, Blizzard RM, Foley TP, Hopwood NJ, Kirkland RJ, Rosenfeld RG, Van Wyk JJ (1986) Lancet i:697–700
Katre NV (1993) Adv Drug Deliv Rev 10: 91 – 114
Keating MJ, Holmes R, Lerner S, Ho DH (1993) Leuk Lymph 10 [Suppl]: 153
Kennel SJ, Falcioni R, Wesley JW (1991) Cancer Res 51:1529-1536 Khazaeli MB (1989) Hybridoma 8: 231 – 239
Khazaeli MB, Conry RM, LoBuglio AF (1994) J Immunother 15: 42 – 52
Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF (1988) J Natl Cancer Inst 80: 937 – 942
Kinsky SC, Nicoletti RA (1977) Annu Rev Biochem 46: 49 – 67
Konno T, Maeda H, Iwai K, Maki S, Tashiro S, Uchida M, Miyauchi Y (1984) Cancer 54: 2367 – 2374
Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, Mochinaga M, Hiraoki T, Yoyokama I (1983) Eur J Cancer Clin Oncol 19: 1053 – 1065
Kopecek J (1981) In: Williams DF (ed) Systematic aspects of biocompatability, vol II. CRC Press, Boca Raton, pp 159 – 180
Kreuter J (1983a) Pharm Acta Helv 58: 196 – 209
Kreuter J (1983b) Pharm Acta Helv 58: 217 – 226
Kreuter J (1983c) Pharm Acta Helv 58: 242 – 250
Kubota K, Yamada T, Ogura A, Ishizak T (1990) J Pharm Sci 79: 179 – 184
Kumar D (1993) Horm Metab Res 25: 360 – 364
Kurokawa T, Iwasa S, Kakinuma A (1989) Biotechnology 7: 1163 – 1176
Kurtz AB, Nabarro JDN (1980) Diabetologia 19: 329 – 334
Kurtzberg J, Asselin B, Popìack D, Grebanier A, Chen R, Franklin A, Scudiery D, Fisherman J (1993) Proc Am Assoc Cancer Res 34: 1807a
Kurtzman SH, Russo A, Mitchell JB, de Graff W, Sindelar WF, Brechbiel MW, Ganson OA, Friedman AM, Hines JJ, Gamson J, Atcher RE (1988) J Natl Cancer Inst 80: 449 – 452
Land VJ, Shuster JJ, Pullen J, Harris M, Krance RA, Castleberry R, Adabutu J, Barboas JL, Rosen D (1989) Proc Am Soc Clin Oncol 8: 215
Larsen GR, Timony GA, Horgan PG, Barone KM, Henson KS, Angus LB, Stoudemire JB (1991) J Biol Chem 266: 8156 – 8161
Larson SM, Carrasquillo JA, Reynolds JC (1984) Cancer Invest 2: 363 – 381
Lau D, Kuzma G, Wei C-M, Livingston DJ, Huiung N (1987) Biotechnology 5: 953 – 958
Le Doussal JM, Gruaz-Guyon A, Martin M, Gautherot E, Delaage M, Barbet J (1990) Cancer Res 50: 3445 – 3452
Lee VHL (1986) Enzymatic barrier to peptide and protein absorption and use of penetration enhancers to modify absorption. In: Davis SS, Ilium L, Tomlinson E (eds) Proceedings of NATO advanced research workshop: advanced drug delivery systems for peptides and proteins. Plenum, Copenhagen, p 87
Lee WY, Sehon AH, Akerblom E (1981) Int Arch Allergy Appi Immunol 64: 100 – 114
Lees A, Finkelman F, Inman JK, Witherspoon K, Johnson P, Kennedy J, Mond JJ (1994) Vaccine 12: 1160 – 1166
Leslie D (1977) Br Med J ii:736–737
Lieberman P, Patterson R, Metz R, Lucena A (1984) JAMA 215: 1106 – 1112
Lindner J, MacNeil LW, Marney S, Conway M, Rivier J, Vale W, Rabin D (1981) J Clin Endocrinol Metab 52: 267 – 270
LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB (1989) Proc Natl Acad Sci USA 86: 4220 – 4224
Lockwood DH, Prout TE (1965) Metabolism 14: 530 – 538
Lopez-Berestein G, Fainstein V, Hopper R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP (1985) J Infect Dis 151: 704 – 710
Lundin K, Berger L, Blomberg F, Wilton P (1991) Acta Paediatr Scand 372: 167 – 169
Machy P, Lerman L (1987) Liposomes. John Libbey Eurotext, Paris
MacLeod JJR (1978) Bull Hist Med 52: 295 – 312
Maeda H (1991) Adv Drug Deliv Rev 6: 181 – 202
Maeda H, Matsumoto T, Konno T, Iwa K, Uida M (1984) J Protein Chem 3: 181 – 193
Maeda H, Seymour LW, Miyamoto Y (1991) Bioconj Chem 3: 351 – 362
Maeda H, Seymour LW, Miyamoto Y (1992) Bioconj Chem 3: 351 – 362
Martin RJ, Denyer SP, Hadgraft J (1987) Int J Pharm 39: 23 – 32
Martis L (1986) 28th Ann Nat Ind Pharm Res Conf Washington
Mashburn LT, Wriston JC (1964) Arch Biochem Biophys 105: 450 – 452
Mayer AM (1982) Diabetes Forecast 35: 44 – 48
Mayer LD, Bally MB, Cullis PB (1986) Biochim Biophys Acta 857: 123 – 126
McGrath KG, Patterson R (1985) Clin Exp Immunol 63: 421 – 426
McGrath KG, Zeffren B, Alexander J, Kaplan K, Patterson RJ (1985) Allergy Clin Immunol 76: 453 – 457
McPherson JM, Livingston DJ (1989) Pharm Tech 13 (9): 32 – 42
Mehta M (ed) (1993) Medical economics. PDR Library on CD-ROM Melino G, Hobbs JR, Radford M, Cooke KB, Evans AM, Castello MA, Forrest DM (1985) Protids Biol Fluids 32: 413 – 447
Melissen PMB, van Vianen W, Bidjal O, van Marion M, Bakker-Woudenberg IAJM (1993) Biotherapy 6: 113 – 124
Meredith R, Khazaeli MB, Plott G, Liu TP, Russell C, Wheeler R, LoBuglio A (1992) Antibody Immunoconj Radiopharmaceut 5: 138
Meyer J, Squier CA, Gerson SJ (eds) (1984) The structure and function of oral mucosa. Pergamon, New York
Mirsky IA, Kawamura K (1966) Endocrinology 78: 1115 – 1119
Miyata K, Nakagawa Y, Nakamura M, Ito T, Sugo K, Fujita T, Tomoda K (1988) Agrie Biol Chem 52: 1575 – 1581
Moseley AB, Caskey CT (1993) Adv Drug Del Rev 12: 131 – 142
Mumtaz M, Bachhawat BK (1992) Biochim Biophys Acta 1117: 174 – 178
Muranishi S (1990) Crit Rev Ther Drug Carrier Syst 7: 1 – 33
Murphy TM, Hadgraft J (1990) In: Scott RC, Guy RH, Hadgraft J (eds) Predictors of percutaneous penetration: methods, measurement, modeling. IBC Technical Services, London, p 333
Murray GJ, Howard KD, Richards S, Barton NW, Brady RO (1991) J Immunol Methods 137: 113 – 120
Musch K, Wolf AS, Lauritzen C (1981) Clin Chim Acta 113: 95 – 100
Nagai TJ (1985) Contr Release 2: 121 – 134
Needham D, Mcintosh TJ, Lasic DD (1992) Biochim Biophys Acta 1108: 40 – 48
Nesbit N, Chard R, Evans A, Karon M, Hammond GD (1979) Am J Pediatr Hematol Oncol 1: 9 – 13
Neuberger MS, Williams GT, Fox RO (1984) Nature 312: 604 – 608
New RRC, Chance ML, Thomas SC, Peters W (1978) Nature 272: 55 – 56
Nishikawa M, Ohtsubo Y, Ohno J, Fujita T, Koyama Y, Yamashita F, Hashida M, Sezaki H (1992) Int J Pharm 85: 75 – 85
Norman C (1985) Science 228: 1176 – 1177
Oppenheim RC (1981) Int J Pharm 8: 217 – 234
Owens DR (1980) Human insulin: clinical pharmacological studies in normal man. MTP Press Lancaster
Pastores GM, Sibille AR, Grabowski GA (1993) Blood. 82: 408 – 416
Peracchia C (1978) Nature 271: 669 – 671
Peracchia C (1978) Nature 271: 669 – 671
PikalMJ (1990) Pharm Res 7: 118 – 126
Preece MA (1986) Experience of treatment with pituitary derived human growth hormone with special reference to immunological aspects. In: Milner MDG, Flodh H (eds) Immunological aspects of human growth hormone. Medical Education Services, Oxford, pp 9 – 16
Reed BR, Chen AB, Tanswell P, Prince WS, Wert RM Jr, Glaesle-Schwartz L, Grossbard EB (1990) Thromb Haemost 64: 276 – 280
Reisner C, Moul DJ, Cudworth AG (1978) Br Med J ii:56
Renold AE, Steinke J, Soeldner JS, Antoniades HN, Smith RE (1966) J Clin Invest 45: 702 – 713
Richards SM, Olson TA, McPherson JM (1993) Blood 82: 1402 – 1409
Ritschel WA, Adolph S, Ritschel GB, Schroeder T (1990) Methods Find Exp Clin Pharmacol 11: 281 – 287
Roberts HW, Cromartie R (1984) Prog Clin Biol Res 150: 1 – 18
Robinson GD (1927) J Pharmacol Exp Ther 32: 81 – 88
Roig de Vargas-Lanares CD (1978) In: Hafez ESE, Evans TN (eds) The human vagina. Elsevier/North Holland Biomedical, Amsterdam, p 193
Rosenblum MG, Cheung L, Murray J (1994) Cancer Bull 46: 34 – 39
Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E III, Nathan DG (1983) Cancer Res 43: 6501 – 5607
Sandhu JS (1992) Grit Rev Biotech 12: 437 – 462
Sato Y, Beutler E (1993) J Clin Invest 91: 1909 – 1917
Schlichtkrull J, Brange K. Christiansen AH, Hallund O, Heding LG, Jorgensen KH (1974) Horm Metab Res 5 [Suppl 1]: 134 – 143
Sehon AH, Lee WY (1981) Int Arch Allergy Appi Immunol 66 [Suppl 1]: 39 – 42
Sela M (1969) Science 166: 1365 – 1374
Senior J, Delgado C, Fisher D, Tilcock C, Gregoriadis G (1991) Biochim Biophys Acta 1062: 77 – 82
Seymour LW, Ulbrich K, Strohalm J, Kopecek J, Duncan R (1990) Biochem Pharmacol 39: 1125 – 1131
Smith DH, Byrn RA, Marsters SA, Gregory T, Groopman JE, Capon DJ (1987) Science 238: 1704
Smith PL, Wall DA, Gochoco C, Wilson G (1992) Adv Drug Del Rev 8: 253 – 290
Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, Kawahata RT, Stoudemire JB, Fradken LB, Bautista EE, Scannon PJ (1987) Cancer Res 47: 1717 – 1723
Starling JJ, Maciak RS, Hinson NA, Nichols CL, Briggs SL, Laguzza BC (1989) Cancer Immunol Immunother 28: 171 – 178
Steiner DF (1967) Trans NY Acad Sci Ser II 30: 60 – 68
Steiner DF, Hallund O, Rubenstein A, Cho S, Bayliss C (1968) Diabetes 17: 725 – 736
Storm G, Wilms HP, Crommelin DJA (1991) Biotherapy 3: 25 – 42
Stratford RE, Lee VHL (1985) J Pharm Sci 74: 731 – 734
Straus EK (1961) Proc Soc Exp Biol Med 106: 617 – 621
Takahaski T, Yamaguchi T, Kitamura K, Suzuyama H, Honda M, Yokota T, Kotanagi H, Takahashi M, Hashimoto H (1988) Cancer 61: 881 – 888
Takakura T, Fujita T, Hashida M, Maeda H, Sezaki H (1989b) J Pharm Sci 78: 219 – 222
Takakura T, Kaneko Y, Fujita T, Hashida M, Maeda H, Sezaki H (1989a) J Pharm Sci 78: 117 – 121
Takakura Y, Fujita T, Hashida M, Maeda H, Sezaki H (1989) J Pharm Sci 78: 219 – 222
Takakura Y, Kaneko Y, Fujita T, Hashida M, Maeda H, Sezaki H (1989) J Pharm Sci 78: 117 – 121
Takakura Y, Masuda S, Tokuda H, Nishikawa M, Hashida M (1994) Biochem Pharmacol 47: 853 – 858
Tallal L, Tan C, Oettgen HE, Wollner N, McCarthy M, Helson L, Burchenal J, Karnofsky D, Murphy ML (1970) Cancer 25: 306 – 320
Tepper RI, Mule JJ (1994) Human Gene Ther 5: 153 – 164
Thistlethwaithe JR Jr, Stuart JK, Mayes JY, Gaber AO, Woodie S, Buckingham MR, Stuart FP (1988) Am J Kidney Dis 11: 112 – 119
Thistlewaithe JR Jr, Cosimi AB, Delmonico FL, Rubin RH, Talkoff-Rubin N, Nelson PW, Fang L, Russell PS (1984) Transplantation 38: 695 – 701
Tomlinson E (1988) Anal Proc 25: 293 – 295
Tomlinson E (1989) Drug News Perspect 2: 5 – 14
Torchilin VP, Klibanov AL, Huang L, O’Donnell S, Nossiff ND, Khaw BA (1992) FASEB J 6: 2716 – 2719
Trouet A, Baurain R, Deprez-De Campeneere D, Masquelier M, Pirson M (1982) Targeting of antitumoral and antiprotozolaldrugs by covalent linkage to protein carriers. In: Grogoriadis G, Senior J, Trouet A (eds) Targeting of drugs. Plenum, New York, pp 19 – 30
Trozak DJ (1985) J Am Acad Derm 13: 247 – 251
Trubetskoy VS, Torchilin VP, Kennel S, Huang L (1992) Biochim Biophys Acta 1131: 311 – 313
Tuchscherer G, Servis C, Corradin G, Blum U, Rivrier J, Mutter M (1992) Protein Sci 1: 1377 – 1386
Tuft L (1928) Ann J Med Scr 176: 707 – 720
Underwood LE, Voina SJ, Van Wyk JJ (1974) J Clin Endocrinol Metab 38: 288 – 297
Veillard MM, Longer MA, Martens TW, Robinson JR (1987) J Contr Release 6: 123 – 132
Vigeral P, Chkoff N, Chatenoud L, Campos H, Lacombe M, Droz D, Goldstein G, Bach JF, Kreis H (1986) Transplantation 41: 730 – 733
Walles M, Daniels M, Ray KP, Cottingham JD, Aston R (1987) Biochem Biophys Res Commun 149: 187 – 193
Wang BS, Szewczyk E, Shieh HM, Hart IC (1990) J Endocrinol 127: 481 – 485
Weiner LM, O’Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES (1989) Cancer Res 49: 4062 – 4067
Weissman G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, Collins T, Gotlieb A, Nagle D (1975) Proc Natl Acad Sci USA 72: 88 – 92
Werier J, Cheung AH, Matas AJ (1991) Lancet 337: 1351
White GC, Taylor RE, Blatt PM (1983) Blood 62: 141 – 145
Widder KJ, Marion PA, Morris RM, Howard FP, Poore GA, Senyei AE (1983) Eur J Cancer Clin Oncol 19: 141 – 147
Widder KJ, Senyei AE, Ranney DF (1979) Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. In: Garattini S et al (eds) Advances in pharmacology and chemotherapy. Academic, New York, pp 213 – 217
Widder KJ, Senyei AE, Sears B (1982) J Pharm Sci 71: 379 – 387
Wileman T, Bennett M, Lilleymann J (1983) J Pharm Pharmacol 32: 762 – 765
Wileman TE, Foster RL, Elliott PNC (1986) J Pharm Pharmacol 38: 264 – 271
Wiles PG, Guy R, Watkins SM, Reeves WG (1983) Br Med J 287: 531
Williams AC, Barry BW (1992) Crit Rev Ther Drug Carrier Syst 9: 305 – 353
Williams JJ (1922) Metab Res 2: 729 – 751
Wilton, Gunnarson (1988) Acta Paediatr Scand 343: 95 – 101
Windsor E, Cronheim GE (1961) Nature 190: 263 – 264
Winter G, Harris WJ (1993) Trends Pharmacol Sci 14: 139 – 143
Witkowski A, Witkowska HE, Smith S (1994) J Biol Chem 269: 379 – 383
Woodie ES, Thistlewaithe JR, Jolliffe LK, Zivin RA, Collins A, Adain JA, Bodmer M, Athwal D, Alegre ML, Bluestone JA (1992) J Immunol 148: 2756 – 2763
Yang R, Lee C, Hsu H, Shorr RGL (1994) FASEB J 8: A94
Yasuda Y, Fujita T, Takakura Y, Hashida M, Sezaki H (1990) Chem Pharm Bull 38: 2053 – 2063
Yoyokama M (1992) Crit Rev Ther Drug Carrier Sys 9: 213 – 248
Zuckerman JE, Murray JL, Rosenblum MG (1987) Proc Am Assoc Cancer Res 28: 1522
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Nucci, M.L., Shorr, R.G.L., Abuchowski, A. (1999). Strategies for Dealing With the Immunogenicity of Therapeutic Proteins. In: Oxender, D.L., Post, L.E. (eds) Novel Therapeutics from Modern Biotechnology. Handbook of Experimental Pharmacology, vol 137. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59990-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-59990-3_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-65927-3
Online ISBN: 978-3-642-59990-3
eBook Packages: Springer Book Archive